Tumour-infiltrating Gr-1 + myeloid cells antagonize senescence in cancer

Nature

Volumn 515, Issue 7525, 2014, Pages 134-137

  Di Mitri, Diletta ^a   Toso, Alberto ^a   Chen, Jing Jing ^a,b   Sarti, Manuela ^a   Pinton, Sandra ^a   Jost, Tanja Rezzonico ^c   D'Antuono, Rocco ^c   Montani, Erica ^c   Garcia Escudero, Ramon ^a,d   Guccini, Ilaria ^a   Da Silva Alvarez, Sabela ^e   Collado, Manuel ^e   Eisenberger, Mario ^f   Zhang, Zhe ^f   Catapano, Carlo ^a   Grassi, Fabio ^c,g   Alimonti, Andrea ^a,b  

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^d CIEMAT   (Spain)

^e Instituto de Salud Carlos III   (Spain)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; DOCETAXEL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR2; GR-1 PROTEIN, MOUSE; IL1RN PROTEIN, MOUSE; INTERLEUKIN 1ALPHA; PTEN PROTEIN, MOUSE; TAXOID;

CANCER; CHEMOTHERAPY; CYTOLOGY; GENE EXPRESSION; GROWTH RATE; IMMUNE RESPONSE; METABOLISM; PHENOTYPE; RODENT; SENESCENCE; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL AGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CYTOLOGY; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; SECRETION (PROCESS); TRANSPLANTATION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

MUS;

ANIMALS; CELL AGING; CELL MOVEMENT; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNITY, INNATE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; MALE; MICE; MYELOID CELLS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, CHEMOKINE; RECEPTORS, INTERLEUKIN-8B; TAXOIDS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84912561603     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13638     Document Type: Article

References (31)

1. Collado, M. & Serrano, M. Senescence in tumours: evidence from mice and humans. Nature Rev. Cancer 10, 51-57 (2010).
2. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
3. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005).
4. Tasdemir, N. & Lowe, S. W. Senescent cells spread the word: non-cell autonomous propagation of cellular senescence. EMBO J. 32, 1975-1976 (2013).
5. Acosta, J. C. et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nature Cell Biol. 15, 978-990 (2013).
6. Orjalo, A. V., Bhaumik, D., Gengler, B. K., Scott, G. K. & Campisi, J. Cell surface-bound IL-1α is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl Acad. Sci. USA 106, 17031-17036 (2009).
7. Alimonti, A. et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120, 681-693 (2010).
8. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nature Rev. Immunol. 12, 253-268 (2012).
9. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007).
10. Kang, T. W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547-551 (2011).
11. Braumüller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361-365 (2013).
12. Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, e59 (2003).
13. + T-cell/ dendritic cell interactions in vivo. Cell. Immunol. 214, 110-122 (2001).
14. Ruiz, E. J., Oeztuerk-Winder, F. & Ventura, J. J. A paracrine network regulates the cross-talk between human lung stem cells and the stroma. Nature Commun. 5, 3175 (2014).
15. Francis, K. & Palsson, B. O. Effective intercellular communication distances are determined by the relative time constants for cyto/chemokine secretion and diffusion. Proc. Natl Acad. Sci. USA 94, 12258-12262 (1997).
16. Ahn, G. O. & Brown, J. M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13, 193-205 (2008).
17. Marigo, I. et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity 32, 790-802 (2010).
18. Lukacs, R. U., Goldstein, A. S., Lawson, D. A., Cheng, D. & Witte, O. N. Isolation, cultivation and characterization of adult murine prostate stem cells. Nature Protocols 5, 702-713 (2010).
19. Horai, R. et al. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187, 1463-1475 (1998).
20. Sgroi, A. et al. Interleukin-1 receptor antagonist modulates the early phase of liver regeneration after partial hepatectomy in mice. PLoS ONE 6, e25442 (2011).
21. Tamassia, N. et al. Uncovering an IL-10-dependent NF-κB recruitment to the IL-1ra promoter that is impaired in STAT3 functionally defective patients. FASEB J. 24, 1365-1375 (2010).
22. Schwarze, S. R., Fu, V. X., Desotelle, J. A., Kenowski, M. L. & Jarrard, D. F. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 7, 816-823 (2005).
23. Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).
24. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev. Immunol. 9, 162-174 (2009).
25. Ewald, J. A., Desotelle, J. A., Wilding, G. & Jarrard, D. F. Therapy-induced senescence in cancer. J. Natl. Cancer Inst. 102, 1536-1546 (2010).
26. Antonarakis, E. S. et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 118, 6063-6071 (2012).
27. ARF) and is amplified in a subset of human breast cancers. Nature Genet. 26, 291-299 (2000).
28. Romanov, S. R. et al. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409, 633-637 (2001).
29. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
30. Alimonti, A. et al. Subtle variations in Pten dose determine cancer susceptibility. Nature Genet. 42, 454-458 (2010).
31. The Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genet. 45, 1113-1120 (2013).